MarketLens

What are the Core Details of the Kuva Labs Acquisition of Lisata Therapeutics

5 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What are the Core Allegations Against Helen of Troy

2 months ago

What is the Core of the Ring Facial Recognition Lawsuit

2 months ago

Is Planet Labs (PL) a Beneficiary of the "Great Rotation" into the Real Economy

4 months ago

What Does Cintas's Acquisition of UniFirst Mean for the Industry

5 months ago

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Quince Therapeutics completed its acquisition of Orphai Therapeutics, adding LAM-001, an inhaled rapamycin formulation for serious pulmonary diseases, to its pipeline. The deal expands Quince's develo...

QNCX

Stock News•1 week ago

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company

Oculis will acquire all worldwide rights to Privosegtor from Accure Therapeutics, terminating its existing license and associated milestone/royalty payments. The deal, announced Aug. 10, 2026, could b...

OCS

Stock News•1 months ago

UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform

Glucotrack and Lōkahi Therapeutics completed their strategic business combination, creating a Lōkahi-controlled public platform to execute a capital-efficient strategy using Lōkahi's ai²-driven asset ...

GCTK

Stock News•2 months ago

Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share

Lisata Therapeutics agreed to be acquired by Kuva Labs for $4 per share in cash, plus up to $3 per share in contingent value rights tied to drug milestones.

LSTA